Pseudomonas aeruginosa isolates harboring acquired drug-resistant genes lead to increased mortality. Here, we have sequenced and annotated the genomes of two multidrug-resistant (MDR) P. aeruginosa isolates and a susceptible P. aeruginosa clinical isolate evidencing divergent antibiotic susceptibilities. Genomic analysis showed insight on the different genomic strategies adapted by P. aeruginosa to combat antimicrobial effects.
seudomonas aeruginosa causes urinary tract infections, bacteremia, gastrointestinal infections, and a variety of systemic infections. Multidrug-resistant (MDR) P. aeruginosa-mediated infections can lead to serious outcomes, such as amputation, or in the worst case, death (1) . The intrinsic and acquired resistance mechanisms of P. aeruginosa include the production of ␤-lactamases, efflux pumps, and target site or outer membrane modifications.
The P. aeruginosa strains VRFPA06 (isolated from blood), VRFPA07 (from a rectal swab), and VRFPA08 (from a urine specimen) were submitted to the L & T Microbiology Research Centre, Sankara Nethralaya, Chennai, Tamil Nadu, India, and studied. The antimicrobial susceptibility result showed that VRFPA06 and VRFPA08 are resistant to aminoglycosides, fluoroquinolones, and ␤-lactams up to carbapenem but were susceptible to the monobactam aztreonam. VRFPA07 is susceptible to all commonly used drugs.
Hence, we determined the draft genome sequences of two MDR P. aeruginosa strains, VRFPA06 and VRFPA08, and one sensitive strain, VRFPA07, to decipher the differences between susceptible and resistant strains at a genomic level, in order to understand the highly combative phenotype of the species. The wholegenome sequencing was performed using the Ion Torrent PGM sequencer with 400-bp read chemistry (Life Technologies). The sequencing protocol was performed according to a previous study (2) . The filtered sequences were made into a reference-guided assembly against the whole-genome sequence of P. aeruginosa PA14 and B136-33 using CLC Genomics Workbench software version 6.5 (CLC bio, Germantown, MD). The assembled data were subjected to RAST annotation (3) and the Prokaryotic Genomes Automatic Annotation Pipeline (PGAAP) (http://www .ncbi.nlm.nih.gov/genomes/static/Pipeline.html). The sequencing and annotation results are given in Table 1 .
The identities of the strains were confirmed by in silico multilocus sequence typing (MLST) (http://cge.cbs.dtu.dk /services/) using the P. aeruginosa MLST database targeting seven potential loci (acsA, aroE, guaA, mutL, nuoD, ppsA, and trpE) and defined as VRFPA06 (sequence type 664 [ST-664]), VRFPA07 (ST-313), and VRFPA08 (ST-823) (4). Further analysis was carried out using the Web server ResFinder (4), an in silico tool used to decipher acquired antimicrobial resistance genes In spite of the genome sizes being similar, the numbers of RNA-coding genes were higher in VRFPA06 (85) and VRFPA08 (82) than in VRFPA07, which has only 67 RNA-coding genes, resulting in a higher expression of proteins among drugresistant strains than in susceptible ones. Further deep analyses will provide better insights on other mechanisms involved in this strains.
Nucleotide sequence accession numbers. This whole-genome shotgun project of P. aeruginosa strains VRFPA06, VRFPA07, and VRFPA08 has been deposited at DDBJ/EMBL/GenBank under accession no. AYSK00000000, AZBO00000000, and AZHU00000000, respectively. The versions described in this paper are the first versions, AYSK00000000.1, AZBO00000000.1, and AZHU00000000.1, respectively.
